

# Coronavirus disease 2019 (COVID-19) Situation Report – 81

Data as received by WHO from national authorities by 10:00 CET, 10 April 2020

## HIGHLIGHTS

- No new country/territory/area reported cases of COVID-19 in the past 24 hours.
- Dr. Bruce Aylward, Special Adviser to WHO’s Director-General, speaking of his recent mission to Spain at a press briefing yesterday, highlighted the need for countries to understand that the virus can overwhelm even the most robust health systems, resulting in the need to entirely reconfigure health sectors in response. Find more about Dr. Aylward’s recent fact-finding mission to Spain [here](#).
- OpenWHO, a web-based learning platform, has launched a new online course *Introduction to Go.Data – Field data collection, chains of transmission and contact follow-up*. The Go.Data tool supports outbreak investigation, focusing on field data collection, contact tracing and visualisation of chains of transmission. It is available to WHO staff around the world, Member States and partners. For more information, please see [here](#).
- As the number of cases continues to climb in Europe, two new WHO tools launched today will help health planners in the European Region prepare for the rapidly increasing number of patients with COVID-19 requiring acute and intensive care in hospitals. For more details, please see [here](#).

## SITUATION IN NUMBERS total (new) cases in last 24 hours

### Globally

1 521 252 confirmed (85 054)  
92 798 deaths (7277)

### European Region

799 696 confirmed (40 035)  
66 213 deaths (4697)

### Region of the Americas

493 173 confirmed (38 463)  
17 038 deaths (2264)

### Western Pacific Region

117 247 confirmed (1395)  
3978 deaths (34)

### Eastern Mediterranean Region

88 657 confirmed (3307)  
4607 deaths (148)

### South-East Asia Region

12 978 confirmed (1402)  
569 deaths (101)


### African Region

8789 confirmed (452)  
382 deaths (33)

### WHO RISK ASSESSMENT

Global Level      Very High

Figure 1. Countries, territories or areas with reported confirmed cases of COVID-19, 10 April 2020



## SURVEILLANCE

**Table 1. Countries, territories or areas with reported laboratory-confirmed COVID-19 cases and deaths. Data as of 10 April 2020\***

Reporting Country/ Territory/Area <sup>†</sup>	Total confirmed ‡ cases	Total confirmed new cases	Total deaths	Total new deaths	Transmission classification <sup>§</sup>	Days since last reported case
<b>Western Pacific Region</b>						
China	83305	56	3345	1	Clusters of cases	0
Republic of Korea	10450	27	208	4	Clusters of cases	0
Australia	6152	100	52	2	Clusters of cases	0
Japan	5347	579	88	3	Clusters of cases	0
Malaysia	4228	109	67	2	Clusters of cases	0
Philippines	4076	206	203	21	Clusters of cases	0
Singapore	1910	287	7	1	Clusters of cases	0
New Zealand	1015	23	1	0	Sporadic Cases	0
Viet Nam	255	4	0	0	Clusters of cases	0
Brunei Darussalam	135	0	1	0	Sporadic Cases	5
Cambodia	118	1	0	0	Sporadic Cases	0
Mongolia	16	0	0	0	Sporadic Cases	1
Fiji	15	0	0	0	Sporadic Cases	2
Lao People's Democratic Republic	15	0	0	0	Sporadic Cases	1
Papua New Guinea	2	0	0	0	Sporadic Cases	1
<b>Territories**</b>						
Guam	128	3	4	0	Clusters of cases	0
French Polynesia	51	0	0	0	Sporadic Cases	1
New Caledonia	18	0	0	0	Sporadic Cases	7
Northern Mariana Islands (Commonwealth of the)	11	0	2	0	Pending	1
<b>European Region</b>						
Spain	152446	5756	15238	683	Pending	0
Italy	143626	4204	18281	612	Pending	0
Germany	113525	5323	2373	266	Pending	0
France	85351	4256	12192	1339	Pending	0
The United Kingdom	65081	4344	7978	881	Pending	0
Turkey	42282	4056	908	96	Community Transmission	0
Belgium	24983	1580	2523	283	Pending	0
Switzerland	23495	785	756	51	Community Transmission	0
Netherlands	21762	1213	2396	148	Pending	0
Portugal	13956	815	409	29	Pending	0
Austria	13248	279	295	22	Pending	0
Russian Federation	11917	1786	94	18	Clusters of cases	0
Israel	9755	351	79	8	Pending	0
Sweden	9141	722	793	106	Pending	0

Ireland	7393	1169	263	28	Pending	0
Norway	6160	150	88	8	Pending	0
Denmark	5635	233	237	19	Pending	0
Poland	5575	370	174	15	Pending	0
Czechia	5569	257	112	13	Pending	0
Romania	5202	441	229	20	Pending	0
Luxembourg	3115	81	52	6	Pending	0
Serbia	2867	201	65	0	Pending	0
Finland	2605	118	42	2	Pending	0
Ukraine	2203	311	69	12	Clusters of cases	0
Greece	1955	71	86	3	Pending	0
Iceland	1648	32	6	0	Pending	0
Croatia	1407	64	20	1	Pending	0
Republic of Moldova	1289	115	29	1	Pending	0
Estonia	1207	22	24	0	Pending	0
Hungary	1190	210	77	11	Pending	0
Slovenia	1124	33	43	3	Pending	0
Belarus	1066	0	13	0	Clusters of cases	1
Lithuania	955	43	15	0	Pending	0
Armenia	937	16	11	1	Clusters of cases	0
Azerbaijan	926	104	9	1	Clusters of cases	0
Bosnia and Herzegovina	875	59	36	1	Community Transmission	0
Kazakhstan	802	75	9	2	Pending	0
Slovakia	701	19	2	0	Pending	0
North Macedonia	663	46	30	0	Clusters of cases	0
Bulgaria	624	31	24	0	Pending	0
Uzbekistan	624	69	3	0	Clusters of cases	0
Andorra	589	23	26	2	Community Transmission	0
Latvia	589	12	2	0	Pending	0
Cyprus	564	38	15	1	Pending	0
Albania	416	7	23	1	Clusters of cases	0
San Marino	344	36	34	0	Community Transmission	0
Malta	337	38	2	1	Pending	0
Kyrgyzstan	298	18	5	1	Pending	0
Montenegro	252	4	2	0	Clusters of cases	0
Georgia	230	16	3	0	Clusters of cases	0
Liechtenstein	79	0	1	0	Pending	1
Monaco	54	0	0	0	Sporadic Cases	1
Holy See	8	0	0	0	Sporadic Cases	1
<b>Territories**</b>						
Kosovo <sup>[1]</sup>	227	3	7	1	Community Transmission	0
Faroe Islands	184	0	0	0	Pending	2
Guernsey	181	15	5	1	Pending	0
Jersey	170	0	3	0	Pending	2
Isle of Man	165	15	1	0	Pending	0
Gibraltar	113	0	1	0	Pending	2

Greenland	11	0	0	0	Pending	4
<b>South-East Asia Region</b>						
India	6412	678	199	33	Clusters of cases	0
Indonesia	3512	556	306	66	Clusters of cases	0
Thailand	2473	50	33	1	Clusters of cases	0
Bangladesh	330	112	21	1	Clusters of cases	0
Sri Lanka	190	1	7	0	Clusters of cases	0
Myanmar	27	5	3	0	Clusters of cases	0
Maldives	19	0	0	0	Clusters of cases	7
Nepal	9	0	0	0	Sporadic Cases	5
Bhutan	5	0	0	0	Sporadic Cases	7
Timor-Leste	1	0	0	0	Sporadic Cases	20
<b>Eastern Mediterranean Region</b>						
Iran (Islamic Republic of)	66220	1634	4110	117	Community Transmission	0
Pakistan	4601	279	66	3	Clusters of cases	0
Saudi Arabia	3287	355	44	3	Clusters of cases	0
United Arab Emirates	2990	331	14	2	Pending	0
Qatar	2376	166	6	0	Pending	0
Egypt	1699	139	118	15	Clusters of cases	0
Morocco	1377	102	97	4	Clusters of cases	0
Iraq	1232	30	69	0	Clusters of cases	0
Kuwait	910	55	1	0	Clusters of cases	0
Bahrain	887	64	5	0	Clusters of cases	0
Tunisia	643	15	25	1	Community Transmission	0
Lebanon	582	7	19	0	Clusters of cases	0
Afghanistan	521	77	15	0	Clusters of cases	0
Oman	484	27	3	1	Clusters of cases	0
Jordan	372	14	7	1	Clusters of cases	0
Djibouti	140	5	1	1	Clusters of cases	0
Libya	24	3	1	0	Clusters of cases	0
Syrian Arab Republic	19	0	2	0	Community Transmission	4
Sudan	15	1	2	0	Sporadic Cases	0
Somalia	12	0	1	0	Sporadic Cases	1
<b>Territories**</b>						
occupied Palestinian territory	266	3	1	0	Clusters of cases	0
<b>Region of the Americas</b>						
United States of America	425889	30859	14665	1925	Community Transmission	0
Canada	19759	1326	461	60	Community Transmission	0
Brazil	15927	2210	800	133	Community Transmission	0
Chile	5972	426	57	9	Community Transmission	0
Ecuador	4965	515	272	30	Community Transmission	0

Peru	4342	1388	121	14	Community Transmission	0
Mexico	3181	396	174	33	Community Transmission	0
Panama	2528	279	63	4	Community Transmission	0
Dominican Republic	2349	393	118	20	Community Transmission	0
Colombia	2054	274	55	5	Community Transmission	0
Argentina	1795	80	67	7	Community Transmission	0
Cuba	515	58	15	3	Clusters of cases	0
Costa Rica	502	19	3	1	Clusters of cases	0
Uruguay	456	32	7	0	Clusters of cases	0
Honduras	343	31	23	1	Clusters of cases	0
Bolivia (Plurinational State of)	264	54	18	3	Clusters of cases	0
Venezuela (Bolivarian Republic of)	166	0	7	0	Clusters of cases	1
Paraguay	124	5	5	0	Clusters of cases	0
Trinidad and Tobago	109	2	8	0	Clusters of cases	0
El Salvador	103	10	5	0	Clusters of cases	0
Guatemala	95	8	3	0	Clusters of cases	0
Barbados	63	0	3	0	Clusters of cases	1
Jamaica	63	0	4	1	Clusters of cases	1
Bahamas	40	4	7	1	Clusters of cases	0
Guyana	37	4	6	1	Clusters of cases	0
Haiti	30	3	2	1	Clusters of cases	0
Antigua and Barbuda	19	0	2	0	Clusters of cases	1
Dominica	15	0	0	0	Clusters of cases	2
Saint Lucia	14	0	0	0	Sporadic Cases	4
Grenada	12	0	0	0	Clusters of cases	5
Saint Kitts and Nevis	11	0	0	0	Sporadic Cases	1
Suriname	10	0	1	0	Sporadic Cases	6
Belize	9	1	1	0	Sporadic Cases	0
Saint Vincent and the Grenadines	8	0	0	0	Sporadic Cases	1
Nicaragua	6	0	1	0	Pending	3
<b>Territories**</b>						
Puerto Rico	683	63	33	9	Clusters of cases	0
Martinique	154	2	6	2	Clusters of cases	0
Guadeloupe	141	2	8	0	Clusters of cases	0
French Guiana	83	6	0	0	Clusters of cases	0
Aruba	82	8	0	0	Clusters of cases	0
United States Virgin Islands	46	1	1	0	Clusters of cases	0
Cayman Islands	45	0	1	0	Clusters of cases	1
Sint Maarten	43	3	8	0	Sporadic Cases	0
Bermuda	39	0	3	1	Clusters of cases	2
Saint Martin	32	1	2	0	Sporadic Cases	0

Curaçao	14	0	1	0	Sporadic Cases	1
Montserrat	8	0	0	0	Sporadic Cases	1
Turks and Caicos Islands	8	0	1	0	Sporadic Cases	2
Saint Barthelemy	6	0	0	0		10
Falkland Islands (Malvinas)	5	0	0	0	Sporadic Cases	1
Anguilla	3	0	0	0	Sporadic Cases	6
British Virgin Islands	3	0	0	0	Sporadic Cases	9
Bonaire, Sint Eustatius and Saba	2	0	0	0	Sporadic Cases	6
Saint Pierre and Miquelon	1	0	0	0	Sporadic Cases	2
<b>African Region</b>						
South Africa	1934	89	18	0	Community Transmission	0
Algeria	1666	94	235	30	Community Transmission	0
Cameroon	730	0	10	0	Clusters of cases	1
Burkina Faso	414	30	19	0	Clusters of cases	0
Niger	410	68	11	0	Clusters of cases	0
Côte d'Ivoire	384	0	3	0	Clusters of cases	1
Mauritius	314	41	7	0	Clusters of cases	0
Ghana	313	0	6	0	Clusters of cases	1
Nigeria	288	12	7	1	Clusters of cases	0
Senegal	250	6	2	0	Clusters of cases	0
Democratic Republic of the Congo	215	8	20	0	Clusters of cases	0
Guinea	194	30	0	0	Clusters of cases	0
Kenya	184	5	7	1	Clusters of cases	0
Rwanda	113	3	0	0	Sporadic Cases	0
Madagascar	95	2	0	0	Clusters of cases	0
Togo	73	3	3	0	Sporadic Cases	0
Congo	60	0	5	0	Clusters of cases	1
Mali	59	3	7	1	Sporadic Cases	0
Ethiopia	56	1	2	0	Sporadic Cases	0
Uganda	53	0	0	0	Sporadic Cases	1
Gabon	44	20	1	0	Sporadic Cases	0
Zambia	39	0	1	0	Sporadic Cases	7
Guinea-Bissau	35	2	0	0	Sporadic Cases	0
Eritrea	33	0	0	0	Sporadic Cases	1
Liberia	31	0	4	0	Sporadic Cases	1
Benin	30	4	1	0	Sporadic Cases	0
United Republic of Tanzania	25	0	1	0	Sporadic Cases	1
Angola	19	0	2	0	Sporadic Cases	1
Equatorial Guinea	18	2	0	0	Sporadic Cases	0
Mozambique	17	0	0	0	Sporadic Cases	1
Namibia	16	0	0	0	Sporadic Cases	4
Botswana	13	7	1	0	Sporadic Cases	0
Eswatini	12	0	0	0	Sporadic Cases	1

Chad	11	1	0	0	Sporadic Cases	0
Seychelles	11	0	0	0	Sporadic Cases	3
Zimbabwe	11	0	3	0	Sporadic Cases	2
Central African Republic	10	0	0	0	Sporadic Cases	1
Malawi	8	0	1	0	Sporadic Cases	2
Cabo Verde	7	0	1	0	Sporadic Cases	3
Sierra Leone	7	0	0	0	Sporadic Cases	1
Mauritania	6	0	1	0	Sporadic Cases	6
Gambia	4	0	1	0	Sporadic Cases	7
São Tomé and Príncipe	4	0	0	0	Pending	3
Burundi	3	0	0	0	Sporadic Cases	6
South Sudan	3	2	0	0	Pending	0
<b>Territories**</b>						
Réunion	376	14	0	0	Clusters of cases	0
Mayotte	191	5	2	0	Clusters of cases	0
<b>Subtotal for all Regions</b>	<b>1520540</b>	<b>85054</b>	<b>92787</b>	<b>7277</b>		
International conveyance (Diamond Princess)	712	0	11	0	Pending	25
<b>Grand total</b>	<b>1521252</b>	<b>85054</b>	<b>92798</b>	<b>7277</b>		

\*Numbers include both domestic and repatriated cases

†The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

‡Case classifications are based on [WHO case definitions](#) for COVID-19.

§Transmission classification is based on a process of country/territory/area self-reporting. Classifications are reviewed on a weekly basis and may be upgraded or downgraded as new information becomes available. Not all locations within a given country/territory/area are equally affected; countries/territories/areas experiencing multiple types of transmission are classified in the highest category reported. Within a given transmission category, different countries/territories/areas may have differing degrees of transmission as indicated by the differing numbers of cases, recency of cases, and other factors.

Terms:


- **No cases:** Countries/territories/areas with no confirmed cases (not shown in table)
- **Sporadic cases:** Countries/territories/areas with one or more cases, imported or locally detected
- **Clusters of cases:** Countries/territories/areas experiencing cases, clustered in time, geographic location and/or by common exposures
- **Community transmission:** Countries/area/territories experiencing larger outbreaks of local transmission defined through an assessment of factors including, but not limited to:
  - Large numbers of cases not linkable to transmission chains
  - Large numbers of cases from sentinel lab surveillance
  - Multiple unrelated clusters in several areas of the country/territory/area

\*\* "Territories" include territories, areas, overseas dependencies and other jurisdictions of similar status

[1] All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

Due to differences in reporting methods, retrospective data consolidation, and reporting delays, the number of new cases may not always reflect the exact difference between yesterday's and today's totals. WHO COVID-19 Situation Reports present official counts of confirmed COVID-19 cases, thus differences between WHO reports and other sources of COVID-19 data using different inclusion criteria and different data cutoff times are to be expected.

Figure 1. Epidemic curve of confirmed COVID-19, by date of report and WHO region through 10 April 2020



## STRATEGIC OBJECTIVES

WHO's strategic objectives for this response are to:

- Interrupt human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread\*;
- Identify, isolate and care for patients early, including providing optimized care for infected patients;
- Identify and reduce transmission from the animal source;
- Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment options, and accelerate the development of diagnostics, therapeutics and vaccines;
- Communicate critical risk and event information to all communities and counter misinformation;
- Minimize social and economic impact through multisectoral partnerships.

\*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in health care settings, implementation of health measures for travelers, awareness-raising in the population and risk communication.

## PREPAREDNESS AND RESPONSE

- To view all technical guidance documents regarding COVID-19, please go to [this webpage](#).
- WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak, clinical management, infection prevention and control in health care settings, home care for patients with suspected novel coronavirus, risk communication and community engagement and Global Surveillance for human infection with novel coronavirus (2019-nCoV).
- WHO is working closely with International Air Transport Association (IATA) and have jointly developed a guidance document to provide advice to cabin crew and airport workers, based on country queries. The guidance can be found on the [IATA webpage](#).
- WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also informing other countries about the situation and providing support as requested.
- WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, mathematical modelling, diagnostics and virology, clinical care and treatment, infection prevention and control, and risk communication. WHO has issued interim guidance for countries, which are updated regularly.
- WHO has prepared a [disease commodity package](#) that includes an essential list of biomedical equipment, medicines and supplies necessary to care for patients with 2019-nCoV.
- WHO has provided recommendations to reduce risk of [transmission from animals to humans](#).
- WHO has published an [updated advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV](#).
- WHO has activated the R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.
- OpenWHO is an interactive, web-based, knowledge-transfer platform offering online courses to improve the response to health emergencies. [COVID-19 courses can be found here](#) and courses in [additional national languages here](#). Specifically, WHO has developed online courses on the following topics:
  - Introduction to Go.Data – Field data collection, chains of transmission and contact follow-up. The Go.Data tool is available globally to WHO staff, member states and partners to support outbreak investigation, focusing on field data collection, contact tracing and visualisation of chains of transmission.
  - A general introduction to emerging respiratory viruses, including novel coronaviruses (available in Arabic, Chinese, English, French, Russian, Spanish, Hindi, Indian Sign Language, Persian, Portuguese, Serbian and Turkish);
  - Clinical care for Severe Acute Respiratory Infections (available in English, French, Russian, Indonesian and Vietnamese);
  - Health and safety briefing for respiratory diseases - ePROTECT (available in Chinese, English, French, Russian, Spanish, Indonesian and Portuguese);
  - Infection Prevention and Control for Novel Coronavirus (COVID-19) (available in Chinese, English, French, Russian, Spanish, Indonesian, Italian, Japanese, Portuguese and Serbian); and
  - COVID-19 Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response (available in English and coming soon in additional languages).
- WHO is providing guidance on early investigations, which are critical in an outbreak of a new virus. The data collected from the protocols can be used to refine recommendations for surveillance and case definitions, to characterize the key epidemiological transmission features of COVID-19, help understand spread, severity, spectrum of disease, impact on the community and to inform operational models for implementation of countermeasures such as case isolation, contact tracing and isolation. Several protocols are available [here](#). One such protocol is for the investigation of early COVID-19 cases and contacts (the “[First Few X \(FFX\) Cases and contact investigation protocol for 2019-novel coronavirus \(2019-nCoV\) infection](#)”). The protocol is designed to gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of

COVID-19 infection detected in any individual country, to inform the development and updating of public health guidance to manage cases and reduce the potential spread and impact of infection.

## RECOMMENDATIONS AND ADVICE FOR THE PUBLIC

If you are not in an area where COVID-19 is spreading or have not travelled from an area where COVID-19 is spreading or have not been in contact with an infected patient, your risk of infection is low. It is understandable that you may feel anxious about the outbreak. Get the facts from reliable sources to help you accurately determine your risks so that you can take reasonable precautions (see [Frequently Asked Questions](#)). Seek guidance from WHO, your healthcare provider, your national public health authority or your employer for accurate information on COVID-19 and whether COVID-19 is circulating where you live. It is important to be informed of the situation and take appropriate measures to protect yourself and your family (see [Protection measures for everyone](#)).

If you are in an area where there are cases of COVID-19 you need to take the risk of infection seriously. Follow the advice of WHO and guidance issued by national and local health authorities. For most people, COVID-19 infection will cause mild illness however, it can make some people very ill and, in some people, it can be fatal. Older people, and those with pre-existing medical conditions (such as cardiovascular disease, chronic respiratory disease or diabetes) are at risk for severe disease (See [Protection measures for persons who are in or have recently visited \(past 14 days\) areas where COVID-19 is spreading](#)).

## CASE DEFINITIONS

WHO periodically updates the [Global Surveillance for human infection with coronavirus disease \(COVID-19\)](#) document which includes case definitions.

For easy reference, case definitions are included below.

### **Suspect case**

A. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset.

**OR**

B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset;

**OR**

C. A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

### **Probable case**

A. A suspect case for whom testing for the COVID-19 virus is inconclusive.

a. Inconclusive being the result of the test reported by the laboratory.

**OR**

B. A suspect case for whom testing could not be performed for any reason.

### **Confirmed case**

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

- Technical guidance for laboratory testing can be found [here](#).

### **Definition of contact**

A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case:

1. Face-to-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes;
2. Direct physical contact with a probable or confirmed case;
3. Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment<sup>1</sup>; OR
4. Other situations as indicated by local risk assessments.

Note: for confirmed asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days *after the date on which the sample was taken* which led to confirmation.

---

<sup>1</sup> World Health Organization. Infection prevention and control during health care when COVID-19 is suspected  
[https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)